Medizin
Refine
Year of publication
- 2016 (316) (remove)
Document Type
- Article (282)
- Doctoral Thesis (14)
- Part of Periodical (11)
- Book (4)
- Contribution to a Periodical (3)
- Conference Proceeding (1)
- Preprint (1)
Has Fulltext
- yes (316)
Is part of the Bibliography
- no (316)
Keywords
- Mitochondria (4)
- apoptosis (4)
- Apoptosis (3)
- Cancer (3)
- HIV (3)
- ROS (3)
- autophagy (3)
- cirrhosis (3)
- ABCB1 (2)
- Aging (2)
- Angiogenesis (2)
- B-cell lymphoma (2)
- Borrelia (2)
- Calcium (2)
- Cell signalling (2)
- Cortex (2)
- CyberKnife robotic radiosurgery (2)
- Diabetes mellitus (2)
- Diagnostic markers (2)
- Exercise (2)
- Experimental models of disease (2)
- Gender (2)
- Heart transplantation (2)
- Immunotherapy (2)
- Infection (2)
- NADPH oxidase (2)
- Pain (2)
- Patient blood management (2)
- Pneumonia (2)
- Proteomics (2)
- Stereotactic body radiation therapy (2)
- Structural plasticity (2)
- VEGF (2)
- atrial fibrillation (2)
- breast cancer (2)
- cancer (2)
- caspase-8 (2)
- complementary and alternative medicine (2)
- development (2)
- diagnosis (2)
- glioblastoma (2)
- hepatitis C (2)
- human (2)
- liver transplantation (2)
- mitosis (2)
- particulate matter (2)
- renal cell carcinoma (2)
- surgery (2)
- ubiquitination (2)
- A/D transition (1)
- ABS (1)
- AGC kinase (1)
- AIH immunopathogenesis (1)
- AJAP1 (1)
- APMPPE - acute posterior multifocal placoid pigment epitheliopathy (1)
- APP (1)
- ARDS (1)
- Abdominal infections (1)
- Academic medicine (1)
- Access (1)
- Acute calcolous cholecystitis (1)
- Acute leukemia (1)
- Acute myeloid leukemia (1)
- Adherence junctions (1)
- Adolescents (1)
- Adverse events (1)
- Air traffic (1)
- All-trans retinoic acid (1)
- Allergic asthma (1)
- Allogeneic hematopoietic stem (1)
- Allogeneic stem cell transplantation (1)
- Ameloblastoma (1)
- Anaemia (1)
- Anatomy (1)
- Anemia (1)
- Anti platelet therapy (1)
- Anti-tumor immunity (1)
- Antibiotic (1)
- Antibiotic stewardship (1)
- Anticoagulation (1)
- Antimicrobial resistance (1)
- Antivenom (1)
- Arrhythmia/all (1)
- Ascites (1)
- Aspergillus fumigatus (1)
- Atherosclerosis (1)
- Atrial fibrillation (1)
- Atxn2 (1)
- Aurora (1)
- Autologous stem cell transplantation (1)
- Automated Tube Potential Selection (1)
- Automatic Environmental Tobacco Smoke Emitter (1)
- Autophagy (1)
- Azan trichrome stain (1)
- B-cell non-Hodgkin lymphoma (1)
- BMC (1)
- Backpropagating action potential (1)
- Bacterial infection (1)
- Bacterial pathogenesis (1)
- Bariatric surgery (1)
- Beatmung (1)
- Becton Dickinson (1)
- Benefit (1)
- Bibliometric analysis (1)
- Biliary tree stones (1)
- Bisphosphonates (1)
- Blood loss (1)
- Blood transfusion (1)
- Bone defect (1)
- Bone regeneration (1)
- Brain injury (1)
- Breast cancer (1)
- Breech delivery (1)
- Bungarus niger (1)
- C. elegans (1)
- CA1 (1)
- CD95/Fas receptor (1)
- CDK inhibitor (1)
- CIK cells (1)
- CNS cancer (1)
- COPD (1)
- CRISPR/Cas9 (1)
- CT pulmonary angiography (1)
- CT radiation exposure (1)
- CUELA (1)
- CYBA/p22phox (1)
- CYP1A1 (1)
- Cancer Staging (1)
- Cancer detection (1)
- Capecitabine (1)
- Carbapenem-resistente Gram-negative Bakterien (CRGN) (1)
- Carbapenemasen (1)
- Cardiac (1)
- Cardiac output (1)
- Cardiology (1)
- Cardiomyocyte signaling pathways (1)
- Cardioprotection (1)
- Cardiovascular disease (1)
- Catch-up validation study (1)
- Catheter ablation (1)
- Cats (1)
- Cdk1/cyclin B1 (1)
- Celiac disease (1)
- Cell salvage (1)
- Cell therapy (1)
- Cerebellum (1)
- Cerebral cortex (1)
- Cesarean delivery (1)
- Checkpoint inhibitor (1)
- Chemical modification (1)
- Chemiluminescence (1)
- Chemorefractory advanced gastric cancer (1)
- Chemotherapy (1)
- Children (1)
- Chimerism (1)
- Cholecystectomy (1)
- Chondral Lesion (1)
- Chorion (1)
- Chronic hepatitis (1)
- Chronic inflammation (1)
- Cigarettes (1)
- Claudin 5 (1)
- Clinical competence (1)
- Clinical genetics (1)
- Clinical skills (1)
- Clinical trial (1)
- Clinical trials (1)
- Clonidine (1)
- Clustering (1)
- Cofilin (1)
- Collagen antibody-induced arthritis (1)
- Comorbidities (1)
- Compartmental modeling (1)
- Complementary medicine (1)
- Complex I (1)
- Compliance (1)
- Computed tomography pulmonary angiography (CTPA) (1)
- Computer simulation (1)
- Conduct disorder (1)
- Congenital ocular motor apraxia (1)
- Conventional Chemotherapeutic (1)
- Cord blood transplantation (1)
- Costs (1)
- Couch tracking (1)
- Craniomandibular disorders (1)
- Critical haematocrit (1)
- Croatia (1)
- Cross-contamination (1)
- Cryo-electron microscopy (1)
- Cryoballoon (1)
- Cytotoxic CD8+ T cell (1)
- DKK1 (1)
- DNA damage (1)
- DNA methylation (1)
- DNA replication (1)
- DNA-protein crosslinks (1)
- Daptomycin (1)
- Databases (1)
- Decision making (1)
- Decision trees (1)
- Decision-making (1)
- Decolonization (1)
- Delegation (1)
- Delivery mode (1)
- Delivery quality assurance (1)
- Dendritic spines (1)
- Denosumab (1)
- Density equalizing (1)
- Density equalizing mapping (1)
- Dentistry (1)
- Desinfektion von Flugzeugen (1)
- Desmin (1)
- Diagnosis (1)
- Digital breast tomosynthesis (DBT) (1)
- Digital mammography (1)
- Disinfection of aircraft (1)
- Distribution (1)
- Dogs (1)
- Domestic (1)
- Drug targeting (1)
- Drug therapy (1)
- Dual-Source CT (1)
- Dvc1 (1)
- E-learning (1)
- E. coli (1)
- EQ (1)
- EQ-5D (1)
- ET (1)
- Early goal-directed therapy (1)
- Echocardiography (1)
- Eclampsia (1)
- Economic evaluation (1)
- Economic impact (1)
- Electron transport chain (1)
- Electrotonic analysis (1)
- Elimination (1)
- Emotion regulation (1)
- Emphysema (1)
- Employment effect (1)
- Endometriosis (1)
- Endoscopic ultrasound (1)
- Endothelial permeability (1)
- Entorhinal cortex lesion (1)
- EnvZ signalling (1)
- Envenomation (1)
- Epidermolysis bullosa simplex with muscular dystrophy (1)
- Eradication (1)
- Erythema migrans (1)
- Erythrocytes (1)
- Europe (1)
- Evaluation (1)
- Everolimus (1)
- Evidence-based medicine (1)
- Ewing sarcoma (1)
- Excitability (1)
- Exercise Metabolism (1)
- Extracellular RNA (eRNA) (1)
- FOLFIRI (1)
- Fc receptor (1)
- Feedback (1)
- Females (1)
- Fetal bovine serum (1)
- Fibrosis (1)
- First-line combination antiretroviral therapy (1)
- Fleas (1)
- Flexible Endoscopic Evaluation of Swallowing (1)
- Folic acid (1)
- Follow-up (1)
- Functional capacity (1)
- Functional clustering (1)
- GSK2334470 (1)
- GVHD (1)
- Gallbladder percutaneous drainage (1)
- Gastritis (1)
- Gastrointestinal bleeding (1)
- Gastrointestinal neoplasm (1)
- Gender analysis (1)
- Gene expression (1)
- General clinical cardiology (1)
- General practice/family medicine (1)
- Genetics research (1)
- Germany (1)
- Gestational diabetes (1)
- Gimbaled tracking (1)
- Gram-positive infection (1)
- Granule cell (1)
- Gross tumor volume optimization (1)
- Growth cone (1)
- Guideline (1)
- Guidelines (1)
- H3 receptor (1)
- HMA (1)
- Hausarztpraxis (1)
- Health care workers (1)
- Heart regeneration (1)
- Hemodilution (1)
- Hemodynamic management (1)
- Hemostasis (1)
- Hepatitis C virus (1)
- Hepatitis c (1)
- Herd immunity (1)
- High-dose chemotherapy (1)
- Highly infectious diseases (1)
- Hochansteckende Krankheiten (1)
- Hodgkin lymphoma (1)
- Hodgkin-Lymphom (1)
- Homeostasis (1)
- Homeostatic plasticity (1)
- Homocysteine (1)
- Hospital (1)
- Hospitals (1)
- Household contacts (1)
- Hrvaška (1)
- Human behaviour (1)
- Human physiology (1)
- Humans (1)
- IAP proteins (1)
- IGRA (1)
- IL-11 (1)
- IL-13 (1)
- IL-22 (1)
- IL-6 (1)
- Immobilization (1)
- Immune response (1)
- Immunity (1)
- Immunocompromised (1)
- Immunology and Microbiology Section (1)
- Immunosuppressive agents (1)
- Immunosuppressive therapy (1)
- In vitro (1)
- In vivo (1)
- Incidence (1)
- Individualized intervention (1)
- Indoor air pollution (1)
- Induced pluripotent stem cells (1)
- Infant (1)
- Inflow obstruction (1)
- Influenza (1)
- Intensive care (1)
- Intensive care unit (1)
- Interdisciplinarity (1)
- Intermediate filaments (1)
- Intratumoral (1)
- Iron deficiency anemia (1)
- Ischemia/reperfusion injury (1)
- Ischemia–reperfusion injury (1)
- Itpr1 (1)
- Jaw (1)
- Joint destruction (1)
- Joubert syndrome (1)
- Kidney transplantation (1)
- Kiefer (1)
- Kim-1 (1)
- Kinases (1)
- Kinematic posture analysis (1)
- Krait (1)
- Kraniomandibuläre Dysfunktion (1)
- LC3B (1)
- LDL-cholesterol (1)
- LOS (1)
- LTBI (1)
- Lactation (1)
- Learning outcomes (1)
- Lecture (1)
- Left ventricular assist device (1)
- Left ventricular non-compaction, (1)
- Lenalidomide (1)
- Length of stay (1)
- Lice (1)
- Lineage tracing (1)
- Lipid metabolism (1)
- Lipid signaling (1)
- Lipid signalling (1)
- Liquid filled MicroLion ion chamber array (1)
- Liver cirrhosis (1)
- Liver metastases (1)
- Long-term care (1)
- Longitudinal (1)
- Low back pain (1)
- Ltbp4 (1)
- Lucigenin (1)
- Luftverkehr (1)
- Lungenkontusion (1)
- Lyme borreliosis (1)
- Lyme disease (1)
- Lyme disease - Borreliosis (1)
- MEDIC (1)
- MLC tracking (1)
- MLL-rearranged leukemia (1)
- MMF (1)
- MPA (1)
- MPN (1)
- MPN-U (1)
- MR-based histology (1)
- MRI (1)
- MRSA (1)
- Machine-learning (1)
- Macrophage Transdifferentiation (1)
- Magnetic resonance (1)
- Major bleeding (1)
- Major infection after cardiac surgery (1)
- Mammary gland (1)
- Manufacturing (1)
- Mapping (1)
- Measles (1)
- Medizinische Fachangestellte (1)
- Meldepflicht (1)
- Membrane assays (1)
- Mental health (1)
- Mesenchymal stem/stromal cells (1)
- Metabolic diseases (1)
- Metastatic breast cancer (1)
- Methicillin resistance (1)
- MicroRNAs (miRNAs) (1)
- Migrants (1)
- Minimal residual disease (1)
- Mitochondrial complex I (1)
- Modified FDI criteria (1)
- Molar tooth sign (1)
- Molecular biology (1)
- Monacolin K (1)
- Morphological modeling (1)
- Mortality (1)
- Motor control (1)
- Multi-resistant pathogens (1)
- Multidetector Computed Tomography (1)
- Multimodal imaging (1)
- Multiple myeloma (1)
- Multiple sclerosis (1)
- Multivariate analysis (1)
- Muscarinic acetylcholine receptor (1)
- Muscular diseases (1)
- Musculoskeletal system (1)
- Muskuloskeletales System (1)
- NADH:ubiquinone oxidoreductase (1)
- NHE (1)
- NK cell (1)
- NK cell subset (1)
- NO (1)
- NS3 protease inhibitor (1)
- NSF (1)
- NXF1 (1)
- Nackenmuskulatur (1)
- Neck muscles (1)
- Neoplasms (1)
- Nerve regeneration (1)
- Nervous system diseases (1)
- Neurodegeneration (1)
- Neuroinflammation (1)
- Neurotoxicity (1)
- Nitric oxide (1)
- Non-RCT (1)
- Non-alcoholic fatty liver disease (1)
- Non-coding RNAs (1)
- Non-neuronal cholinergic system (1)
- Nonsteroidal anti-inflammatory drugs (1)
- Nox (1)
- Nox4 (1)
- Nrf2 (1)
- Nucleophosmin-1 (1)
- OECD performance standards (1)
- OPRM1 methylation (1)
- OSCE (1)
- Olfactory system (1)
- Oncolytic adenovirus (1)
- Open source concept (1)
- Oppositional defiant disorder (1)
- Organ motion (1)
- Osmosensing (1)
- Osteoporosis (1)
- Ovarian cancer (1)
- Oxygen consumption (1)
- PAR (1)
- PDK1 (1)
- PELICAN (1)
- PIF pocket (1)
- PMF (1)
- PV (1)
- Parainfluenza (1)
- Parkinson's disease (1)
- Particulate matter (1)
- Patellofemoral Joint (1)
- Pathogen reduction (1)
- Pdgfrβ (1)
- Peer-feedback (1)
- Peer-teaching (1)
- Pegylated liposomal doxorubicin (1)
- Persistence (1)
- Pharmacological treatment (1)
- Pharmacology (1)
- Phosphorylation (1)
- Physicians (1)
- Placental growth factor (1)
- Platelet (1)
- Platelet lysate (1)
- Platelet releasate (1)
- Plectin (1)
- Plk1 inhibitors (1)
- Polo-like kinase 3 (1)
- Polyhexanide (1)
- Population-based screening (1)
- Porin regulation (1)
- Post-translational modifications (1)
- Pre-economic effects (1)
- Pre-emptive immunotherapy (1)
- Pre-treatment drug resistance mutations (1)
- Preclinical research (1)
- Predictive medicine (1)
- Preeclampsia (1)
- Pregnancy (1)
- Primary care (1)
- Primärversorgung (1)
- Produkte zur Desinfektion (1)
- Progranulin (1)
- Protein aggregates (1)
- Proximal humeral fracture (1)
- Pseudo HE-images (1)
- Pulse contour analysis (1)
- Pulse pressure variation (1)
- Qualifikation (1)
- Quality of care (1)
- Quantitative MRI (1)
- RCT (1)
- RIPK3 (1)
- ROS generation (1)
- RT-qPCR (1)
- Radiofrequency (1)
- Raman spectroscopy (1)
- Randomised controlled trial (1)
- Randomized controlled trial (1)
- Rational use (1)
- Reactive oxygen species (1)
- Recall rate (1)
- Reconstructed human epidermis (1)
- Red blood cells (1)
- Red yeast rice (1)
- Redox (1)
- Regression analysis (1)
- Rehospitalization (1)
- Relapse (1)
- Relaxometry (1)
- Remote ischemic conditioning (1)
- Renal cell carcinoma (1)
- Renal function (1)
- Research architecture (1)
- Residential care (1)
- Resin composites (1)
- Respiration (1)
- Respiratory signs and symptoms (1)
- Respiratory syncytial virus (1)
- Rheumatoid arthritis (1)
- Robotic tracking (1)
- Roma women (1)
- Rora (1)
- Rotorest (1)
- Ruijs-Aalfs syndrome (1)
- Ryanodine (1)
- S. cerevisiae (1)
- SAP (1)
- SCT (1)
- SPARTAN (1)
- SPRTN (1)
- SR protein (1)
- SRSF3 (1)
- SRSF7 (1)
- STAT3 (1)
- STIR (1)
- SW480 Cell (1)
- Salmonella infection (1)
- Schmerz (1)
- Science structure (1)
- Scientometric analysis (1)
- Scientometrics (1)
- Sclerostin (1)
- Second stage of labor (1)
- Second-line treatment (1)
- Sensorimotor training (1)
- Sensory neuron (1)
- Sepsis-bundle (1)
- Sequence (1)
- Signaling (1)
- Signaling ROS (1)
- Skeletal muscle (1)
- Skeletal muscle fiber-type switching (1)
- Skills training (1)
- Skin irritation test (1)
- Skin manifestation (1)
- Smac (1)
- Smooth muscle cell (1)
- Snakebite (1)
- Socioeconomic status (1)
- Software tool (1)
- Spectral library (1)
- Sphere Formation Assay (1)
- Splice variants (1)
- Standardized operating procedures (1)
- Standardverfahren (1)
- Stroke (1)
- Stroke prevention (1)
- Stroke volume variation (1)
- Substances for disinfection (1)
- Sulfhydryl-reactivity (1)
- Sulfur metabolism (1)
- Sunitinib (1)
- Superinfection (1)
- Superoxide (1)
- Surgery (1)
- Surgical risk (1)
- Surveillance (1)
- Sympathicolysis (1)
- Synaptic plasticity (1)
- Synaptopodin (1)
- Synovial inflammation (1)
- Systematic review (1)
- Systemic treatment (1)
- T cell/histiocyte rich large B cell lymphoma (1)
- T cells (1)
- T1 (1)
- T84 colon carcinoma cells (1)
- TAX1BP1 (1)
- TRAIL (1)
- Target identification (1)
- Targeted therapy (1)
- Tax effect (1)
- Tgfβ (1)
- Therapeutics (1)
- Thermodilution (1)
- Thermoplasma (1)
- Thiol redox modification (1)
- Thromboembolism (1)
- Thrombosis (1)
- Thrombosis/hypercoagulable states (1)
- Ticks (1)
- Topoisomerase (1)
- Transfusion (1)
- Translational research (1)
- Transmembrane communication (1)
- Transmission (1)
- Trauma (1)
- Travellers (1)
- Treatment (1)
- Treatment protocol (1)
- Tumor suppressor protein (1)
- Tumorsphere Formation (1)
- Tyrosine kinase inhibitor (1)
- Tyrosine kinase inhibitor mTOR inhibition (1)
- Tyrosine kinases (1)
- USP9X (1)
- Undergraduate training (1)
- Upper respiratory tract infection (1)
- Urban (1)
- VE-cadherin (1)
- Vaccination (1)
- Vaginal breech delivery (1)
- Vaginal delivery (1)
- Value-added effect (1)
- Vascular permeability (1)
- Viral load (1)
- Virological failure (1)
- Voltage attenuation (1)
- WRNIP1 (1)
- XIAP (1)
- Zoonosis (1)
- acetaminophen (1)
- acute coronary syndrome (1)
- acute liver injury (1)
- acute myeloid leukemia (AML) (1)
- adalimumab (1)
- adenomatous polyposis (1)
- adenosine (1)
- adhesion (1)
- adipose tissue-derived stem cell (1)
- advance directive (1)
- advanced care planning (1)
- age-related macular degeneration (1)
- aging (1)
- allogeneic stem cell transplantation (1)
- allosteric regulation (1)
- alternative 3′ end processing (1)
- anal carcinoma (1)
- angiogenesis (1)
- angioplasty (1)
- angiopoietin-2 (1)
- angiopoietin-like 3 (ANGPTL3) (1)
- animal host (1)
- animal models (1)
- antenatal characteristics (1)
- antenatalne značilnosti (1)
- anti-citrullinated protein antibodies (1)
- anticoagulants (1)
- anticonvulsant activity (1)
- antiviral (1)
- antiviral therapy (1)
- archaea (1)
- archaeosomes (1)
- artery (1)
- astrocytoma (1)
- asymmetric hearing (1)
- auditory development (1)
- autoantibodies (1)
- automatic environmental tobacco smoke emitter (1)
- behavior (1)
- binaural cochlear implants (1)
- bio-absorbable mesh (1)
- biochemistry (1)
- biological mesh (1)
- biomarker (1)
- bone marrow metastasis (1)
- bone metastasis (1)
- brain metastases (1)
- brain states (1)
- brainmass (1)
- brainsize (1)
- bronchial allergen challenge (1)
- burden of illness (1)
- c1orf124 (1)
- cancer care (1)
- cancer care providers (1)
- cancer screening (1)
- candidate genes (1)
- carbapenem-resistant Gram-negative bacteria (CRGN) (1)
- carbapenemases (1)
- carboxyfluorescein (1)
- cardiovascular magnetic resonance (1)
- carotid (1)
- catheterization/diagnostic interventional (1)
- cell biology (1)
- cell death (1)
- cell transplantation (1)
- cells (1)
- central nervous system infection (1)
- chemokines: CYP2D6 model (1)
- chemoradiotherapy (1)
- chromosome segregation (1)
- chronic hepatitis C (1)
- chronic viral hepatitis (1)
- cigarette smoke (1)
- clusteranalysis (1)
- cochlear implant (1)
- cold tolerance (1)
- compaction (1)
- complement (1)
- compliance (1)
- connectional fingerprint (1)
- connective tissue (1)
- continuing education (1)
- cortical layers and areas (1)
- cross-modal plasticity (1)
- cytokine (1)
- cytokines (1)
- deaf white cat (1)
- deafness (1)
- decision making (1)
- dedifferentiation (1)
- dentate gyrus (1)
- dentist (1)
- depression (1)
- deprivation (1)
- desensitization (1)
- desmoplastic stroma (1)
- diclofenac (1)
- differentiation (1)
- diffuse large B cell lymphoma (1)
- diffusion MRI (1)
- diffusion tensor imaging (1)
- direct antiviral agents (1)
- drug resistance (1)
- eNOS (1)
- editorials (1)
- electrocardiography (1)
- endothelial (1)
- endothelial cells (1)
- endothelial receptor expression (1)
- environmental tobacco smoke (1)
- epilepsy (1)
- erosions (1)
- eutheria (1)
- exercise testing (1)
- exome sequencing (1)
- familial colorectal cancer (1)
- fasting (1)
- fear conditioning (1)
- fear generalization (1)
- fibrosarcoma (1)
- fracture (1)
- freeze avoidance (1)
- gadobutrol (1)
- gender (1)
- gene expression (1)
- gene expression profiling (1)
- gene expression profiling (GEP) (1)
- generic preparedness (1)
- glucocorticoids (1)
- gold nanoparticles (1)
- governance (1)
- graph theory (1)
- green fluorescent protein (1)
- guideline (1)
- health-related quality of life (1)
- hepatitis c (1)
- hepatocytes (1)
- hepatotoxicity (1)
- herb induced liver injury (HILI) (1)
- herbal drug (1)
- herbal hepatotoxicity (1)
- hereditary angioedema (1)
- hereditary tumor syndromes (1)
- high-dose chemotherapy (1)
- histamine (1)
- histological validation (1)
- homoarginine (1)
- hormones (1)
- host response (1)
- human brain (1)
- human gingival fibroblasts (1)
- human natural killer cell (1)
- hypoxia (1)
- iCLIP (1)
- immune evasion (1)
- immune reconstitution (1)
- immune response (1)
- immunocompromised patient (1)
- immunologic (1)
- immunostaining (1)
- in situ hybridization (1)
- in situ vaccine (1)
- incisional hernia (1)
- influenza pandemic (1)
- information needs (1)
- innate immunity (1)
- insertable cardiac monitor (1)
- interaural time difference (1)
- interferon (1)
- interferon-free antiviral treatment (1)
- invasion (1)
- irritable bowel syndrome (1)
- isomeric antagonists (1)
- kinase regulation (1)
- kinetische Therapie (1)
- laser (1)
- laser based cell manipulation (1)
- laser microdissection (1)
- leukocytes (1)
- life span (1)
- liposomes (1)
- living will (1)
- local control (1)
- low-dose imaging (1)
- lymphoma pathogenesis (1)
- l‐arginine:glycine amidinotransferase (1)
- mRNA export (1)
- macrophages (1)
- magnetic resonance imaging (1)
- mammals (1)
- management (1)
- mandatory reporting system (1)
- mantle cell lymphoma (1)
- massive parallel sequencing (1)
- maturation (1)
- medical history (1)
- menthol (1)
- men’s (1)
- meta-analysis (1)
- metabolism (1)
- metalloprotease (1)
- miRNA (1)
- microbiome (1)
- microwave ablation (1)
- mismatch repair (1)
- mitotic arrest (1)
- molecular dynamics (1)
- mouse (1)
- multi-drug resistance (1)
- multidrug-resistant Gram-negative bacteria (MRGN) (1)
- multiresistente Gram-negativen Stäbchenbakterien (MRGN) (1)
- neuroblastoma (1)
- neuroinformatics (1)
- neuromodulation (1)
- nodular lymphocyte predominant Hodgkin lymphoma (1)
- noise intervention measures (1)
- nonnucleoside polymerase inhibitor (1)
- non‑Hodgkin's lymphoma (1)
- nuclear hormone receptor (1)
- nursery schools (1)
- observational study (1)
- occupational health (1)
- occupational stress (1)
- oncology (1)
- oral enzyme combination (1)
- orthodontist (1)
- osteoarthritis (1)
- osteoporosis (1)
- osteoporosis treatment (1)
- oval split ring resonator (1)
- p21 phosphorylation (1)
- p21 stability (1)
- pandemic preparedness (1)
- patient’s desires (1)
- pattern (1)
- perforin (1)
- perfusion (1)
- perinatal HIV infection (1)
- periodontal diseases (1)
- periodontitis (1)
- peripheral blood stem cell transplant (1)
- pirinixic acid (1)
- pirinixic acid derivative (1)
- pixantrone (1)
- pol g (1)
- pollen allergy (1)
- polo-like kinase (1)
- polycystic kidney (1)
- post hoc study (1)
- prefrontal cortex (1)
- prevention (1)
- progenitor (1)
- progeria (1)
- prognosis (1)
- proliferation (1)
- prophylaxis (1)
- protein kinase (1)
- proximal tubule (1)
- psoriatic arthritis (1)
- public health. (1)
- radiological (1)
- randomized controlled trial (1)
- rat model (1)
- real-world data (1)
- renal impairment (1)
- retuximab (1)
- risk communication (1)
- rituximab (1)
- romske ženske (1)
- salvage therapy (1)
- schizophrenia (1)
- senescence (1)
- sensory deprivation (1)
- sex‑determining region Y-box 11 (1)
- signature (1)
- single‐photon emission (1)
- size of cigarettes (1)
- skin conductance (1)
- skin involvement (1)
- sleep (1)
- slow-wave rhythms (1)
- smac mimetic (1)
- small compounds (1)
- sound analyses (1)
- sphingolipid (1)
- spirochetes (1)
- stellate reticulum (1)
- stereoselectivity (1)
- stress (1)
- stress response (1)
- stroke prevention (1)
- sulforaphane (1)
- survey (1)
- systematic review (1)
- targeted therapy (1)
- teratoma (1)
- testosterone (1)
- tetraether lipid (1)
- theranostics (1)
- therapy at the end of life (1)
- tobacco taxation (1)
- tolerance (1)
- training (1)
- treatment (1)
- trophiclevel (1)
- tumor immune escape (1)
- ubiquitin (1)
- ubiquitin coat (1)
- ubiquitin-binding zinc finger (1)
- ultra-high field MRI (1)
- vascular endothelial growth factor (1)
- vertebrates (1)
- vessel density (1)
- virological failure (1)
- waking state (1)
- wax layer (1)
- western blotting (1)
- winter survival (1)
- work ability (1)
- working conditions (1)
- xenobiotics (1)
- xenophagy (1)
- young people (1)
- μ-opioid receptor regulation (1)
Institute
- Medizin (316)
- Präsidium (11)
- Biowissenschaften (8)
- Exzellenzcluster Makromolekulare Komplexe (6)
- Biochemie und Chemie (5)
- Pharmazie (5)
- Sonderforschungsbereiche / Forschungskollegs (4)
- Georg-Speyer-Haus (3)
- MPI für Hirnforschung (3)
- Sportwissenschaften (3)
The CDK inhibitor SNS-032 had previously exerted promising anti-neuroblastoma activity via CDK7 and 9 inhibition. ABCB1 expression was identified as major determinant of SNS-032 resistance. Here, we investigated the role of ABCB1 in acquired SNS-032 resistance. In contrast to ABCB1-expressing UKF-NB-3 sub-lines resistant to other ABCB1 substrates, SNS-032-adapted UKF-NB-3 (UKF-NB-3rSNS- 032300nM) cells remained sensitive to the non-ABCB1 substrate cisplatin and were completely re-sensitized to cytotoxic ABCB1 substrates by ABCB1 inhibition. Moreover, UKF-NB-3rSNS-032300nM cells remained similarly sensitive to CDK7 and 9 inhibition as UKF-NB-3 cells. In contrast, SHEPrSNS-0322000nM, the SNS-032-resistant sub-line of the neuroblastoma cell line SHEP, displayed low level SNS-032 resistance also when ABCB1 was inhibited. This discrepancy may be explained by the higher SNS-032 concentrations that were used to establish SHEPrSNS-0322000nM cells, since SHEP cells intrinsically express ABCB1 and are less sensitive to SNS-032 (IC50 912 nM) than UKF-NB-3 cells (IC50 153 nM). In conclusion, we show that ABCB1 expression represents the primary (sometimes exclusive) resistance mechanism in neuroblastoma cells with acquired resistance to SNS-032. Thus, ABCB1 inhibitors may increase the SNS-032 efficacy in ABCB1-expressing cells and prolong or avoid resistance formation.
The Hepatitis C virus (HCV) infects more than 170 million individuals worldwide and causes challenging HCV-related diseases. Unfortunately, there is no vaccine available. Therefore, a better understanding of the HCV life cycle is urgently needed to develop more effective and better tolerated therapies.
It has been reported that the secretory pathway plays an essential role for the release of HCV, and the SNARE complexes are a central factor controlling intracellular vesicular trafficking. Recently, our group observed that α-taxilin that binds to free syntaxin 4 prevents the SNARE complex formation and exerts an inhibitory effect on the release of HCV particles. Therefore, it was analyzed whether the t-SNARE protein syntaxin 4 is involved in the HCV life cycle.
An increased intracellular amount of syntaxin 4 was found in HCV-positive cells, while the level of syntaxin 4-specific transcripts was decreased as observed in HCV-positive Huh7.5 cells and in HCV-infected primary human hepatocytes (PHH). Since in HCV-positive cells a significant longer half-life of syntaxin 4 was found, the decreased expression is overcompensated, leading to the elevated amount of syntaxin 4. Overexpression of syntaxin 4 increases the amount of secreted infectious viral particles, while silencing of syntaxin 4 expression decreases the number of released viral particles, which indicates that HCV could use the SNARE-dependent secretory pathway for viral release. Confocal immunofluorescence microscopy and co-immunoprecipitation experiments revealed that syntaxin 4 interacts with HCV core and NS5A. To identify the binding domain, various mutants of syntaxin 4 were generated. Based on these mutants, it was found that the H3 domain of syntaxin 4 interacts with core. These data show that the t-SNARE protein syntaxin 4 is an essential cellular factor for HCV morphogenesis and secretion.
HCV induces autophagy, and in HCV-infected cells a major fraction of the de novo synthesized viral particles is not released but intracellularly degraded. Syntaxin 17 is an autophagosomal SNARE required for the fusion of autophagosomes with lysosomes to form autolysosomes and thereby to deliver the enclosed contents for degradation. Therefore, we aim to investigate whether syntaxin 17 is a relevant factor for the HCV life cycle by regulating the fusion between autophagosomes and lysosomes. It was found that HCV-positive cells possess a decreased amount of syntaxin 17, and HCV reduces the intracellular level of syntaxin 17 by NS5A-mediated interruption of c-Raf signaling, which triggers the syntaxin 17 transcription, and by HCV-dependently induced autophagy. Overexpression of syntaxin 17 decreases the intracellular amount of viral particles and reduces the number of released infectious viral particles by favoring the formation of autolysosomes, in which HCV particles can be degraded. Vice versa, inhibition of syntaxin 17 expression by specific siRNAs results in an elevated amount of intracellular viral particles and increases the number of released viral particles by impaired autophagosome-lysosome fusion. Confocal immunofluorescence microscopy analyses show a fraction of core protein in autophagosomes as stained by lysotracker and the autophagy maker p62. These data identify syntaxin 17 as a novel factor controlling the release of HCV and reveal the autophagosome-autolysosome fusion as an essential step affecting the equilibrium between the release of infectious viral particles and lysosomal degradation of intracellular viral particles.
Taken together, these data identify the t-SNARE proteins syntaxin 4 and syntaxin 17 as essential cellular factors for HCV morphogenesis and secretion.
Prognostische Faktoren und das Outcome von Patienten mit einem primären Glioblastom sind in der Fachliteratur gut beschrieben. Im Gegensatz dazu gibt es wenige vergleichbare Informationen zu Patienten mit einem sekundären Glioblastom. Das Ziel dieser Arbeit war es, das Outcome von Patienten mit einem sekundären Glioblastom zu beurteilen und prognostische Faktoren in Be-zug auf das Gesamtüberleben zu identifizieren.
Dazu wurde die interne Datenbank des Universitätsklinikums Frankfurt/Main von Patienten mit Hirntumoren retrospektiv nach klinischen Daten durchsucht. Alle Patienten hatten ein histologisch gesichertes WHO Grad II oder III Gliom und anschließend ein WHO Grad IV sekundäres Glioblastom. Paraffiniertes Hirntumorgewebe wurde auf Mutationen der Isocitrat Dehydrogenase-1 (IDH1) mittels einer immunhistochemischen Färbung mit einem R132H (clone H09) spezifischen Antikörper untersucht. Eine uni- und multivariate statistische Analyse wurde durchgeführt, um Faktoren zu ermitteln, die potentiell das Gesamt-überleben beeinflussen könnten.
Es wurden 45 Patienten mit einem histologisch gesicherten sekundären Glioblastom untersucht. Das mediane Alter betrug 41 Jahre. 14 Patienten unterzogen sich einer radiologisch kompletten Resektion des sekundären Glioblastoms, 31 Patienten wurden subtotal reseziert oder biopsiert. Initial ist bei 37 Patienten ein astrozytärer Tumor nachgewiesen worden und die restlichen Patienten litten an Oligodendrogliomen oder gemischten Gliomen; bei der initialen Diagnose wurden 17 WHO Grad II und 28 WHO Grad III Tumoren fest-gestellt. Die mediane Zeit zwischen Ursprungstumor und dem Auftreten des sekundären Glioblastoms betrug 158,9 Wochen. Das mediane Gesamtüberleben betrug 445 Tage nach der Diagnose eines sekundären Glioblastoms. Mutationen des IDH1 (R132H) Proteins wurden bei 24 Patienten festgestellt und fehlten bei 17 Patienten; bei 4 Patienten konnte keine IDH1 immunhistochemische Färbung durchgeführt werden.
In der univariaten Analyse konnte der Zeitraum zwischen initialer Läsion und dem Progress zu einem sekundären Glioblastom als statistisch signifikanter Einflussfaktor identifiziert werden- Patienten mit einem Zeitraum von mehr als 2 Jahren hatten ein besseres Gesamtüberleben (460 vs. 327 Tage, p = 0,011). Außerdem konnte bei Patienten, die eine kombinierte Radiochemotherapie bekamen, ein besseres Gesamtüberleben nachgewiesen werden als bei Patienten, welche ausschließlich eine Therapieform erhielten (611 vs. 380 Tage, p < 0,001). Weiterhin konnten ein WHO Grad II Ursprungstumor (472 vs. 421 Tage, p = 0,05) und eine Frontalllappenlokalisation des Glioblastoms (472 vs. 425 Ta-ge, p = 0,031) das Überleben steigern.
In der multivariaten Analyse konnte gezeigt werden, dass die Mutation des IDH1 (R132H) Proteins in statistisch signifikanter Weise mit einem längeren Gesamtüberleben assoziiert war (p = 0,012); statistische Signifikanz für ein län-geres Gesamtüberleben bei Patienten mit initial einem WHO Grad II (p = 0,047) und einer Frontallappenlokalisation des Glioblastoms (p = 0,042) stellte sich auch ein. In Bezug auf die Patienten spezifischen Daten wurden zwei Prognosegruppen erstellt; Patienten in der guten Prognosegruppe scheinen einen Benefit von einer totalen Tumorresektion zu haben (p = 0,02), während eine Resektion für die andere Prognosegruppe keine große Rolle spielte (p = 0,926).
Trotz des relativ geringen Erkrankungsalters haben sekundäre Glioblastom Patienten eine schlechte Prognose. Die Ergebnisse dieser Arbeit unterstreichen die Wichtigkeit und den prognostischen Wert der IDH1 Diagnostik, die Notwendigkeit einer kombinierten Radiochemotherapie und eine Risikostratifizierung für eine Prognoseabschätzung anhand der Patienten spezifischen Einflussfaktoren.
Evidence about distribution patterns of brain metastases with regard to breast cancer subtypes and its influence on the prognosis of patients is insufficient. Clinical data, cranial computed tomography (CT) and magnetic resonance imaging (MRI) scans of 300 breast cancer patients with brain metastases (BMs) were collected retrospectively in four centers participating in the Brain Metastases in Breast Cancer Registry (BMBC) in Germany. Patients with positive estrogen (ER), progesterone (PR), or human epidermal growth factor receptor 2 (HER2) statuses, had a significantly lower number of BMs at diagnosis. Concerning the treatment mode, HER2-positive patients treated with trastuzumab before the diagnosis of BMs showed a lower number of intracranial metastases (p < 0.001). Patients with a HER2-positive tumor-subtype developed cerebellar metastases more often compared with HER2-negative patients (59.8% vs. 44.5%, p = 0.021), whereas patients with triple-negative primary tumors had leptomeningeal disease more often (31.4% vs. 18.3%, p = 0.038). The localization of Brain metastases (BMs) was associated with prognosis: patients with leptomeningeal disease had shorter survival compared with patients without signs of leptomeningeal disease (median survival 3 vs. 5 months, p = 0.025). A shorter survival could also be observed in the patients with metastases in the occipital lobe (median survival 3 vs. 5 months, p = 0.012). Our findings suggest a different tumor cell homing to different brain regions depending on subtype and treatment. View Full-Text
NOSTRIN belongs to the family of F-BAR proteins, which are multi-domain adaptor proteins that have emerged as important regulators of membrane remodeling and actin dynamics in a variety of vital cellular processes. They have been analyzed structurally and biochemically and overexpression studies have revealed their potential in inducing membrane curvature and tubulation. Several studies have begun to decipher the function of individual proteins, but the understanding of F-BAR protein functions in vivo is still quite limited. The F-BAR protein NOSTRIN is mainly expressed in endothelial cells and has originally been described as interaction partner of the endothelial nitric oxide synthase (eNOS), modulating eNOS subcellular localization. The phenotypic characterization of NOSTRIN knockout mice revealed decreased nitric oxide (NO) and cGMP levels, an increase in systolic blood pressure and an impairment of the acetylcholine-induced, NO-dependent relaxation of aortic rings from mice with global as well as endothelial cell-specific knockout of the NOSTRIN gene (ECKO) . These findings implied that NOSTRIN plays a role in regulating NO production in vivo, but the underlying molecular mechanisms were unclear. Therefore, this study was aimed at addressing the mechanism causing the inhibited vasodilation specifically upon stimulation with acetylcholine in NOSTRIN KO and ECKO mice, and at exploring additional roles of NOSTRIN in the signal transduction of endothelial cells.
The major acetylcholine receptor that mediates vessel relaxation upon stimulation with acetylcholine is the muscarinic acetylcholine receptor subtype M3 (M3R). In the present study NOSTRIN was identified as novel interaction partner of the M3R and important factor for the correct spatial distribution and functionality of the M3R. Moreover, it provides the first example of an F-BAR protein regulating a GPCR. Confocal immunofluorescence microscopy analysis of isolated aortae from NOSTRIN KO and WT mice indicated that NOSTRIN was necessary for the proper subcellular localization of the M3R and targeted it to the plasma membrane. A series of pulldown experiments revealed a direct interaction of NOSTRIN with the M3R. The binding required the SH3 domain of NOSTRIN and the third intracellular loop of the M3R, which has a recognized role in receptor regulation. The interaction of NOSTRIN with the M3R was confirmed by co-localization of NOSTRIN and the M3R upon overexpression in mammalian cells. Expression levels of the M3R as well as eNOS were not affected by the loss of NOSTRIN in accordance with the finding, that NOSTRIN impacts on the acetylcholine/eNOS signaling axis through regulation of the subcellular trafficking of its binding partners.
Furthermore, there were first indications for a role of NOSTRIN in facilitating the carbachol-induced calcium response in M3R-expressing cells, suggesting that NOSTRIN might influence M3R activation. in the absence of NOSTRIN, the function of the M3R in mammalian cells overexpressing the M3R was markedly impaired, resulting in abolition of the calcium response to the M3R agonist carbachol. In accordance, the activated eNOS fraction associated with the Golgi complex was markedly reduced in aorta explants from NOSTRIN knockout and ECKO mice. Moreover, NOSTRIN knockout inhibited the carbachol-induced, activating phosphorylation of eNOS in murine aortae as well as primary mouse lung endothelial cells confirming its role as important regulator of eNOS activity in vivo.
Purpose: A study of real-time adaptive radiotherapy systems was performed to test the hypothesis that, across delivery systems and institutions, the dosimetric accuracy is improved with adaptive treatments over non-adaptive radiotherapy in the presence of patient-measured tumor motion.
Methods and materials: Ten institutions with robotic(2), gimbaled(2), MLC(4) or couch tracking(2) used common materials including CT and structure sets, motion traces and planning protocols to create a lung and a prostate plan. For each motion trace, the plan was delivered twice to a moving dosimeter; with and without real-time adaptation. Each measurement was compared to a static measurement and the percentage of failed points for γ-tests recorded.
Results: For all lung traces all measurement sets show improved dose accuracy with a mean 2%/2 mm γ-fail rate of 1.6% with adaptation and 15.2% without adaptation (p < 0.001). For all prostate the mean 2%/2 mm γ-fail rate was 1.4% with adaptation and 17.3% without adaptation (p < 0.001). The difference between the four systems was small with an average 2%/2 mm γ-fail rate of <3% for all systems with adaptation for lung and prostate.
Conclusions: The investigated systems all accounted for realistic tumor motion accurately and performed to a similar high standard, with real-time adaptation significantly outperforming non-adaptive delivery methods.
BACKGROUND: Polyclonal anti-thymocyte globulins (ATGs) are immunosuppressive drugs widely used in induction of immunosuppression and treatment of acute rejection after solid organ transplantation. We have previously demonstrated that ATGs bind to endothelial cells in vitro, and are able to modulate ECs. The aim of this study was to investigate the binding of ATGs to endothelial cells under in vivo conditions.
MATERIAL AND METHODS: Muscle biopsies from extremities of cynomolgus monkeys were obtained after ischemia/reperfusion at 4°C. ATGs (Thymoglobulin, Sanofi-Aventis, France; 1 mg/kg) were added to the blood 30 min prior to the reperfusion. Biopsies (n=10) of patients undergoing heart transplantation and preoperatively treated with ATGs (Thymoglobulin, Sanofi-Aventis, France; 1.5 mg/kg) as induction therapy were also analyzed 6 hours and 7 days after induction. Binding of ATGs to ECs was analyzed with an anti-rabbit IgG antibody by means of immunohistochemistry.
RESULTS: Binding of ATGs to endothelial cells could be demonstrated in vivo in our animal experiments 4 hours after reperfusion, as well as in the clinical biopsies 6 hours after induction of immunosuppression in heart transplant patients, showing a preferred localization in post-capillary veins. No expression of ATGs on the endothelial surface could be observed after 7 days, suggesting that ATGs may be washed out from the endothelial surface in a time-dependent manner.
CONCLUSIONS: Our results show that ATGs are able to bind to endothelial cells in an experimental model and in clinical practice, supporting preconditioning strategies with ATGs in solid organ transplantation.
Introduction: In the time of increasing resistance and paucity of new drug development there is a growing need for strategies to enhance rational use of antibiotics in German and Austrian hospitals. An evidence-based guideline on recommendations for implementation of antibiotic stewardship (ABS) programmes was developed by the German Society for Infectious Diseases in association with the following societies, associations and institutions: German Society of Hospital Pharmacists, German Society for Hygiene and Microbiology, Paul Ehrlich Society for Chemotherapy, The Austrian Association of Hospital Pharmacists, Austrian Society for Infectious Diseases and Tropical Medicine, Austrian Society for Antimicrobial Chemotherapy, Robert Koch Institute.
Materials and methods: A structured literature research was performed in the databases EMBASE, BIOSIS, MEDLINE and The Cochrane Library from January 2006 to November 2010 with an update to April 2012 (MEDLINE and The Cochrane Library). The grading of recommendations in relation to their evidence is according to the AWMF Guidance Manual and Rules for Guideline Development.
Conclusion: The guideline provides the grounds for rational use of antibiotics in hospital to counteract antimicrobial resistance and to improve the quality of care of patients with infections by maximising clinical outcomes while minimising toxicity. Requirements for a successful implementation of ABS programmes as well as core and supplemental ABS strategies are outlined. The German version of the guideline was published by the German Association of the Scientific Medical Societies (AWMF) in December 2013.
Background: Infection is a main cause of morbidity and mortality after heart surgery, with multi-resistant pathogens increasingly representing a challenge. Daptomycin provides bactericidal activity against gram-positive organisms that are resistant to standard treatment including vancomycin.
Methods: A cohort of cardiac surgical patients, treated with daptomycin for major infection at two tertiary care centers, were retrospectively studied with a particular focus on the type of infection, causative pathogens and co-infections, daptomycin dosage, adverse events and outcome in order to provide evidence for the efficiency and safety of daptomycin in a distinct high-risk patient population.
Results: Sixty-five patients (87.7 % males, 60.4 ± 13.5 years) who had undergone aortic surgery (20.0 %), ventricular assist device (VAD) implantation (21.5 %), combined procedures (21.5 %), coronary artery bypass grafting (12.3 %), isolated valve surgery (15.4 %) and heart transplantation (7.7 %) were diagnosed with catheter-related infection (26.1 %), valve endocarditis (18.8 %), sternal wound (13.0 %), VAD-associated (11.6 %), cardiac implantable electrophysiological device (CIED)-associated (4.1 %), respiratory tract (4.3 %), bloodstream (4.3 %) and other infection (4.3 %). In 13.0 %, no focus of infection was identified though symptoms of severe infection were present. The most frequent pathogens were Staphylococcus epidermidis (30.4 %), Staphylococcus aureus (23.1 %) and Enterococcus species (10.1 %). Daptomycin doses ranging from 3 mg/kg every 48 h to 10 mg/kg every 24 h were administered for 15.4 ± 11.8 days. 87.0 % of the cases were classified as success, 7.2 % as treatment failure and 5.8 as non-evaluable. Adverse events were limited to one case of mild and one case of moderate neutropenia with recovery upon termination of treatment.
Conclusion: Daptomycin proved safe and effective in major infection in high-risk cardiac surgical patients.